title: [Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy].
abstract: For the purpose of local control and breast conservation, intraarterial infusion chemotherapy combined with radiotherapy has been indicated in patients with locally advanced breast cancer both in primary and recurrent cases. The present series, evaluated during the past 4 years, consisted of 15 patients 35-83 years of age, with invasive ductal carcinoma, including 10 with primary breast cancer (stage IIIb: 1; IV: 9) and 5 with postoperative recurrence (stage IIIb: 2, IV: 3). Intraarterial chemotherapy is started, basically infusing ADM 50 mg, MMC 10 mg and CDDP 50 mg into the internal thoracic and/or subclavian artery 1-3 times, followed by reduction surgery (quadrantectomy: 4, wide resection: 2) and radiotherapy to the breast, supraclavicular, parasternal and cervical regions according to tumor extent. Local response after arterial infusion was CR: 2, PR: 10, NC: 3 (response rate: 73%). The response rate of distant metastases after arterial infusion was 73%. Of 10 patients with primary breast cancer, recurrence was noted in 1. Breast conservation was successful in 8 of 10 patients. One of them, in stage IIIb, has survived for 4.5 years with no evidence of disease and with breast conservation. Five patients with postoperative recurrence showed CR with no recurrence after intraarterial chemotherapy and radiotherapy. Acute skin reaction occurred in 6 patients, and was especially frequent in patients with postoperative recurrence (4 of 5). According to these results, combined therapy affords breast conservation even in patients with locally advanced breast cancer, and improves patient's QOL in stage IV.
authors.affiliation: Department of Radiology, Tenri Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Murakami
authors.forename: E
authors.initials: E
authors.lastname: Yoden
authors.forename: K
authors.initials: K
authors.lastname: Kono
authors.forename: Y
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Maetani
authors.forename: H
authors.initials: H
authors.lastname: Sai
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: R
authors.initials: R
authors.lastname: Sasaki
authors.forename: N
authors.initials: N
authors.lastname: Kazawa
authors.forename: A
authors.initials: A
authors.lastname: Sano
authors.forename: Y
authors.initials: Y
authors.lastname: Kuroda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000532:radiotherapy*; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin